Marker Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Alyeska Investment Group, L.P., along with Alyeska Fund GP, LLC and Anand Parekh, reported a 9.9% beneficial ownership stake in Marker Therapeutics, Inc., totaling 1,280,952 shares.
NASDAQ
SCHEDULE 13G/A: Blue Owl Capital Holdings LP Discloses Amended 9.99% Stake in Marker Therapeutics, Inc.
Blue Owl Capital Holdings LP has filed an amended Schedule 13G, reporting a 9.99% beneficial ownership stake in Marker Therapeutics, Inc., comprising common stock and exercisable warrants.
NASDAQ
SCHEDULE 13G: Blue Owl Capital Holdings LP Discloses 5.18% Passive Stake in Marker Therapeutics, Inc.
Blue Owl Capital Holdings LP has reported a passive 5.18% beneficial ownership stake in Marker Therapeutics, Inc. as of December 31, 2024.
NASDAQ
Alyeska Investment Group, L.P., along with its affiliates, has disclosed a passive beneficial ownership of 9.99% in Marker Therapeutics, Inc., totaling 1,069,659 shares as of December 31, 2024.